olverembatinib

Sponsor Ascentage Pharma Group International · listed as AAPG

READOUT Phase 3 Confidence: medium Source: clinicaltrials

olverembatinib is a clinical-stage drug asset sponsored by Ascentage Pharma Group International, listed as AAPG. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Mar 31, 2027 (day precision, medium confidence), tied to trial NCT06640361. The asset is in Phase 3 and currently recruiting, studied in GIST. It appears across 3 tracked trials in the CSA sample.

Next catalyst

Event typeREADOUT

Expected date2027-03-31

As disclosedMar 31, 2027

Date precisionday

Confidencemedium

Verify at source →

Trial & sponsor

Trial (NCT)NCT06640361

PhasePHASE3

StatusRECRUITING

Lead sponsorAscentage Pharma Group Inc.

Listed asAAPG

Condition(s)GIST

Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.

This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.

Get the full dataset — $499 → More AAPG catalysts